Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program

• Paul Emery ,

  * E-mail: p.emery@leeds.ac.uk

  Affiliations Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  ⨯
• William Rigby,

  Affiliation The Geisel School of Medicine at Darthmouth, Lebanon, New Hampshire, United States of America

  ⨯
• Paul P. Tak,

  Current address: GlaxoSmithKline, Stevenage, United Kingdom

  Affiliation Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands

  ⨯
• Thomas Dörner,

  Affiliation Charité University Hospitals and DRFZ, Berlin, Germany

  ⨯
• Ewa Olech,

  Affiliation University of Nevada School of Medicine, Las Vegas, Nevada, United States of America

  ⨯
• Carmen Martin,

  Affiliation Roche Products, Ltd, Welwyn Garden City, United Kingdom

  ⨯
• Laurie Millar,

  Affiliation Roche Products, Ltd, Welwyn Garden City, United Kingdom

  ⨯
• Helen Travers,

  Affiliation Roche Products, Ltd, Welwyn Garden City, United Kingdom

  ⨯
• Elena Fisheleva

  Affiliation Roche Products, Ltd, Welwyn Garden City, United Kingdom

  ⨯